What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?-Reference-Cited by-同舟云学术

What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

Published:2019-05-22 Issue:1 Volume:177 Page:231-232
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Maltoni Roberta,Bravaccini Sara^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05275-z.pdf

Reference4 articles.

1. de Nonneville A, Jauffret C, Gonçalves A et al (2019) Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05160-9

2. de Melo Gagliato D, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744

3. Curigliano G, Burstein HJ, Winer EP et al (2017) De-escalating and escalating treatments for early-stage breast cancer the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol 28(8):1700–1712

4. Farolfi A, Scarpi E, Rocca A et al (2015) Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer 51(14):1874–1881

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer;JNCI: Journal of the National Cancer Institute;2023-02-10